AWHL · Aspira Women's Health Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Given the above conditions, there is substantial doubt about our ability to continue as a going concern within one year after the date these consolidated interim financial statements are issued.”View the 10-Q filed Aug 14, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross profit margin | 55.3% | the three months ended June 30, 2026 filing | — |
| Ova1Plus Average Unit Price (AUP) | $409 | the three months ended June 30, 2026 filing | — |
| Ova1Plus tests performed | 3,889 | the three months ended June 30, 2026 filing | — |
| OvaSuite tests performed | 5,059 | the three months ended June 30, 2026 filing | — |
| OvaWatch Average Unit Price (AUP) | $388 | the three months ended June 30, 2026 filing | — |
| OvaWatch tests performed | 1,170 | the three months ended June 30, 2026 filing | — |
| Total OvaSuite Average Unit Price (AUP) | $402 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AWHL
this stock
Aspira Women's Health Inc.
|
$9.80M | -66.7% | +8475.0% | — | 0.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$251.20B | +18.6% | +14.5% | 36.6 | 1.5% |
|
DHR
Danaher Corp /De/
|
$157.64B | -2.0% | +8.5% | 39.8 | 1.3% |
|
NTRA
Natera, Inc.
|
$57.57B | +77.2% | -2.8% | — | 4.4% |
|
A
Agilent Technologies, Inc.
|
$48.56B | +27.1% | +6.4% | 33.9 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- -767 sh
- Top holder
- Motiv8 Investments LLC
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AWHL | -19.2% | -16.0% | -47.5% | -8.7% | -66.7% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -18.1% | -15.4% | -55.6% | -9.5% | -79.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.